Meta-analysis: Remission and response from control arms of randomized trials of biological therapies for active luminal Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 27, Issue 12, 2008, Pages 1210-1223

  Tine F ^a   Rossi, F ^b   Sferrazza, A ^b   Orlando, A ^b   Mocciaro, F ^b   Scimeca, D ^b   Olivo, M ^b   Cottone, M ^b  

^a VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALICAFORSEN; BIOLOGICAL FACTOR; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; ETANERCEPT; FONTOLIZUMAB; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 6 ANTIBODY; MITOGEN ACTIVATED PROTEIN KINASE P38; NATALIZUMAB; ONERCEPT; PLACEBO; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; STEROID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTICLE; BIOLOGICAL THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CROHN DISEASE; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFICACY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ADULT; BIOLOGICAL THERAPY; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 43849087995     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03681.x     Document Type: Article

References (45)

1. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003 3 : 521 33.
2. Mac Donald TT, Monteleone G. Immunity, inflammation, and allergy in the gut. Science 2005 307 : 1920 5.
3. Ardizzone S, Bianchi Porro G. Biologic therapy for inflammatory bowel disease. Drugs 2005 65 : 2253 86.
4. Stokkers PCF, Hommes DW. Novel biological therapies for inflammatory bowel disease. Curr Treat Options Gastroenterol 2006 9 : 201 10.
5. Ellenberg SS, Temple R. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: Practical issues and specific cases. Ann Intern Med 2000 133 : 464 70.
6. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984 86 : 249 66.
7. Su C, Lichtenstein GR, Krok K, et al. A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology 2004 126 : 1257 69.
8. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976 70 : 439 44.
9. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996 17 : 1 12.
10. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986 7 : 177 88.
11. Thompson SG, Higgins JPT. How should meta-regression analyses be undertaken and interpreted? Statist Med 2002 21 : 1559 73.
12. Thompson SG, Sharp SG. Explaining heterogeneity in meta-analysis: a comparison of methods. Statist Med 1999 18 : 2693 708.
13. Egger M, Smith GD, Altman D. Systematic Reviews in Health Care, 2nd edn. London : BMJ Books, 2001.
14. Stack WA, Mann SD, Roy AJ, et al. Randomised controlled trials of CDP571 antibody for tumor necrosis factor-α in Crohn's disease. Lancet 1997 349 : 521 4.
15. Targan SR, Hanauer SB, van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 1997 337 : 1029 35.
16. Van Deventer SJH, Elson CO, Fedorak RN, for the Crohn's Disease Study Group. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Gastroenterology 1997 113 : 383 9.
17. Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, et al. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 1998 114 : 1133 42.
18. Sands BE, Bank S, Sninsky CA, et al. Preliminary evaluation of safety and activity of recombinant human Interleukin 11 in patients with active Crohn's disease. Gastroenterology 1999 117 : 58 64.
19. Fedorak RN, Gangl A, Elson CO, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. Gastroenterology 2000 119 : 1473 82.
20. Schreiber S, Fedorak RN, Nielsen OH, et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Gastroenterology 2000 119 : 1461 72.
21. Gordon FH, Lai CWY, Hamilton MI, et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alfa-4 integrin in active Crohn's disease. Gastroenterology 2001 121 : 268 74.
22. Sandborn WJ, Feagan BG, Hanauer SB, et al. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology 2001 120 : 1330 8.
23. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized double-blind, placebo-controlled trial. Gastroenterology 2001 121 : 1088 94.
24. Sands BE, Winston BD, Salzberg B, et al. Randomized controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease. Aliment Pharmacol Ther 2002 16 : 399 406.
25. Gosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med 2003 348 : 24 32.
26. Ito H, Takazoe M, Fukuda Y, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004 126 : 989 96.
27. Mannon PJ, Fuss IJ, Mayer L, et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004 351 : 2069 79.
28. Sandborn WJ, Feagan BG, Radford-Smith G, et al. CDP571, a humanised monoclonal antibody to tumor necrosis factor α, for moderate or severe Crohn's disease: a randomized, double blind, placebo controlled trial. Gut 2004 53 : 1485 93.
29. Winter TA, Wight J, Ghosh S, et al. Intravenous CDP870, a PEGylated Fab fragment of a humanized antitumour necrosis fctor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study. Aliment Pharmacol Ther 2004 20 : 1337 46.
30. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005 353 : 1912 25.
31. Schreiber S, Rutgeers P, Fedorak RN, et al. A randomized, placebo-controlled trial of Certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005 129 : 807 18.
32. Korzenik JR, Dieckgraefe BK, Valentine JF, et al. Sargramostin for Active Crohn's disease. N Engl J Med 2005 352 : 2193 201.
33. Hanauer SB, Sandborn WJ, Rutgeers P, et al. Human anti-tumor necrosis factor monoclonal antibody (Adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006 130 : 323 33.
34. Hommes DW, Mikhajlova TL, Stoinov S, et al. Fontolizumab, a humanized anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut 2006 55 : 1131 7.
35. Reinish W, Hommes DW, Van Assche G, et al. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patient with moderate to severe Crohn's disease. Gut 2006 55 : 1138 44.
36. Rutgeerts P, Sandborn WJ, Fedorak RN, et al. Onercept for moderate to severe Crohn's disease: a randomized, double-blind, placebo controlled trial. Clin Gastroenterol Hepatol 2006 4 : 888 93.
37. Schreiber S, Feagan B, D'Haens G, et al. Oral p38 mitogen activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006 4 : 325 34.
38. Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial. Gastroenterology 2007 132 : 1672 83.
39. Sandborn WJ, Rutgeers P, Enns R, et al. Adalimumab induction therapy for Crohn's disease previously treated with Infliximab. A randomized trial. Ann Intern Med 2007 146 : 829 38.
40. Yacyshyn B, Chey WY, Wedel MK, et al. A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor ofintercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease. Clin Gastroenterol Hepatol 2007 5 : 215 20.
41. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007 357 : 228 38.
42. Sands BE, Ooi CJ. A survey of methodological variation in the Crohn's Disease Activity Index. Inflamm Bowel Dis 2005 11 : 133 8.
43. Sands BE, Steinhart AH, Lewis JD, et al. Optimal Crohn's Disease Activity Index (CDAI) response criteria is defined by decrease ≥100 points. Gastroenterology 2003 124 : A206.
44. Thompson SG, Higgins JPT. Can meta-analysis help target interventions at individuals most likely to benefit? Lancet 2005 365 : 341.
45. Meyers S, Janowitz HD. "Natural history" of Crohn's disease. An analytic review of the placebo lesson. Gastroenterology 1984 87 : 1189 92.